Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
William J. Rifkin, Rami S. Kantar, MD, Safi Ali-Khan, Natalie M. Plana, J. Rodrigo Diaz-Siso, MD, Manos Tsakiris, PhD, MSc, and Eduardo D. Rodriguez, MD, DDS
Facial transplantation provides a viable option for those patients with severe facial defects who are more likely to adapt to their new facial appearance.
AMA J Ethics. 2018;20(4):309-323. doi:
10.1001/journalofethics.2018.20.4.peer1-1804.
Physician-assisted doping of athletes has transformed high-performance sport into a chronically overmedicated subculture and spread so-called hormonal rejuvenation to the general public.
Marwan Hariz, MD, PhD and Jordan P. Amadio, MD, MBA
Deep brain stimulation (DBS) for enhancements of non-disease states is ethically indefensible given our incomplete knowledge of this technology. Attention should instead be focused on increasing access to DBS for patients with illnesses potentially treatable by the procedure.
Concerns about the deleterious effects of stress on the mind and body have led to the beginnings of a stress vaccine, an injection that will reduce these effects.
Jonathan M. Metzl, MD, PhD and Dorothy E. Roberts, JD
The call for structural competency encourages medicine to broaden its approach to matters of race and culture so that it might better address both individual-level doctor and patient characteristics and institutional factors.
Clinicians' reluctance to engage in environmental interventions for children's psychiatric illnesses, which may seem to implicate parents, may stem from a desire to stand apart from mid-twentieth-century psychiatrists who blamed mothers for pediatric mental illness.